Exact Sciences: Q2 Earnings Insights

Shares of Exact Sciences EXAS moved lower in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 77.59% over the past year to ($1.03), which missed the estimate of ($0.76).

Revenue of $434,819,000 higher by 61.72% from the same period last year, which beat the estimate of $421,280,000.

Looking Ahead

Exact Sciences Raises FY21 Revenue Guidance From $1.69B-$1.735B To $1.705B-$1.745B vs $1.72B Est.

How To Listen To The Conference Call

Date: Jul 28, 2021

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.exactsciences.com%2F&eventid=3196007&sessionid=1&key=22F0BC4D0AB5C447153C61D493318FAC&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $159.54

52-week low: $70.75

Price action over last quarter: Up 4.89%

Company Overview

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!